Get started
ReutersReuters

Immuneering To Discuss Recently Announced Overall Survival Data From Phase 2A Clinical Trial Of Atebimetinib + Mgnp In First-Line Pancreatic Cancer Patients On September 29

RefinitivLess than 1 min read
IMRX

Immuneering Corp IMRX:

  • IMMUNEERING TO DISCUSS RECENTLY ANNOUNCED OVERALL SURVIVAL DATA FROM PHASE 2A CLINICAL TRIAL OF ATEBIMETINIB + MGNP IN FIRST-LINE PANCREATIC CANCER PATIENTS ON MONDAY, SEPTEMBER 29, 2025

North AmericaReutersUS stocks
refinitivrefinitiv
© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html
Login or create a forever free account to read this news

More news from Reuters